Last reviewed · How we verify
Singulair and Xyzal
At a glance
| Generic name | Singulair and Xyzal |
|---|---|
| Also known as | coadministration of Singulair and Xyzal |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PK and Safety Study of HCP1102, HGP0813 and HGP1408 (PHASE1)
- Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination (PHASE1)
- Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients (PHASE3)
- A Drug Interaction Study of Montelukast and Levocetirizine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Singulair and Xyzal CI brief — competitive landscape report
- Singulair and Xyzal updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI